X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs GLENMARK PHARMA - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD GLENMARK PHARMA STRIDES SHASUN LTD/
GLENMARK PHARMA
 
P/E (TTM) x 14.1 13.6 103.3% View Chart
P/BV x 1.9 3.8 49.9% View Chart
Dividend Yield % 0.5 0.3 164.4%  

Financials

 STRIDES SHASUN LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-16
GLENMARK PHARMA
Mar-16
STRIDES SHASUN LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4131,262 111.9%   
Low Rs848672 126.3%   
Sales per share (Unadj.) Rs353.3270.6 130.6%  
Earnings per share (Unadj.) Rs23.424.9 94.0%  
Cash flow per share (Unadj.) Rs41.034.4 119.1%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.40.2 213.8%  
Book value per share (Unadj.) Rs320.4151.3 211.7%  
Shares outstanding (eoy) m89.35282.16 31.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.23.6 89.5%   
Avg P/E ratio x48.338.9 124.4%  
P/CF ratio (eoy) x27.628.1 98.2%  
Price / Book Value ratio x3.56.4 55.2%  
Dividend payout %21.48.0 265.9%   
Avg Mkt Cap Rs m100,988272,778 37.0%   
No. of employees `0004.710.0 46.8%   
Total wages/salary Rs m4,98813,782 36.2%   
Avg. sales/employee Rs Th6,730.07,614.9 88.4%   
Avg. wages/employee Rs Th1,063.61,374.8 77.4%   
Avg. net profit/employee Rs Th445.5700.2 63.6%   
INCOME DATA
Net Sales Rs m31,56476,340 41.3%  
Other income Rs m1,212356 340.3%   
Total revenues Rs m32,77676,696 42.7%   
Gross profit Rs m5,21314,172 36.8%  
Depreciation Rs m1,5732,691 58.4%   
Interest Rs m1,8031,789 100.8%   
Profit before tax Rs m3,04910,048 30.3%   
Minority Interest Rs m1270-   
Prior Period Items Rs m-270-   
Extraordinary Inc (Exp) Rs m-3710-   
Tax Rs m6893,028 22.7%   
Profit after tax Rs m2,0897,019 29.8%  
Gross profit margin %16.518.6 89.0%  
Effective tax rate %22.630.1 74.9%   
Net profit margin %6.69.2 72.0%  
BALANCE SHEET DATA
Current assets Rs m35,94959,096 60.8%   
Current liabilities Rs m19,40240,018 48.5%   
Net working cap to sales %52.425.0 209.8%  
Current ratio x1.91.5 125.5%  
Inventory Days Days7175 94.6%  
Debtors Days Days127119 106.4%  
Net fixed assets Rs m34,47839,075 88.2%   
Share capital Rs m894282 316.6%   
"Free" reserves Rs m22,60130,281 74.6%   
Net worth Rs m28,63242,703 67.0%   
Long term debt Rs m27,45524,873 110.4%   
Total assets Rs m76,591111,026 69.0%  
Interest coverage x2.76.6 40.7%   
Debt to equity ratio x1.00.6 164.6%  
Sales to assets ratio x0.40.7 59.9%   
Return on assets %5.17.9 64.1%  
Return on equity %7.316.4 44.4%  
Return on capital %8.217.5 46.6%  
Exports to sales %48.143.3 111.2%   
Imports to sales %14.57.4 194.6%   
Exports (fob) Rs m15,19233,044 46.0%   
Imports (cif) Rs m4,5655,672 80.5%   
Fx inflow Rs m16,61236,945 45.0%   
Fx outflow Rs m5,29261,066 8.7%   
Net fx Rs m11,320-24,122 -46.9%   
CASH FLOW
From Operations Rs m7173,449 20.8%  
From Investments Rs m-22,284-8,802 253.2%  
From Financial Activity Rs m29,4886,986 422.1%  
Net Cashflow Rs m8,073934 864.5%  

Share Holding

Indian Promoters % 27.7 48.3 57.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 6.9 547.8%  
FIIs % 8.6 34.4 25.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.5 246.7%  
Shareholders   56,241 56,727 99.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   GSK PHARMA  ASTRAZENECA PHARMA  BIOCON LTD  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare STRIDES SHASUN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Aug 23, 2017 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS